<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Bras Cir Cardiovasc</journal-id><journal-title-group><journal-title>Revista Brasileira de Cirurgia Cardiovascular : &#x000f3;rg&#x000e3;o oficial da Sociedade Brasileira de Cirurgia Cardiovascular</journal-title></journal-title-group><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25372920</article-id><article-id pub-id-type="pmc">4412335</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20140091</article-id><article-categories><subj-group subj-group-type="heading"><subject>Special Articles</subject></subj-group></article-categories><title-group><article-title>Direct intramyocardial transthoracic transplantation of bone marrow
mononuclear cells for non-ischemic dilated cardiomyopathy: INTRACELL, a prospective
randomized controlled trial</article-title><trans-title-group xml:lang="pt"><trans-title>Ensaio cl&#x000ed;nico prospectivo randomizado sobre terapia com c&#x000e9;lulas
mononucleares da medula &#x000f3;ssea para cardiomiopatia dilatada idiop&#x000e1;tica:
INTRACELL</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sant'Anna</surname><given-names>Roberto T.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Fracasso</surname><given-names>James</given-names></name><degrees>MD, MSc</degrees><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Valle</surname><given-names>Felipe H.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Castro</surname><given-names>Iran</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Nardi</surname><given-names>Nance B.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Sant'Anna</surname><given-names>Jo&#x000e3;o Ricardo M.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Nesralla</surname><given-names>Ivo Abrah&#x000e3;o</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Kalil</surname><given-names>Renato A. K.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff01"/><xref ref-type="corresp" rid="c01"/></contrib><aff id="aff01">Cardiology Institute/University Foundation of Cardiology (IC/FUC),
Cardiovascular Surgery Service, Porto Alegre, RS, Brazil</aff></contrib-group><author-notes><corresp id="c01">Correspondence address: Renato Abdala Karam Kalil, Instituto de
Cardiologia/Funda&#x000e7;&#x000e3;o Universit&#x000e1;ria de Cardiologia (IC/FUC), Avenida Princesa Isabel,
395 - Santana, Porto Alegre, RS Brazil - Zip Code: 90620-000. E-mail:
<email>kalil.pesquisa@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Sep</season><year>2014</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Sep</season><year>2014</year></pub-date><volume>29</volume><issue>3</issue><fpage>437</fpage><lpage>447</lpage><history><date date-type="received"><day>20</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>07</day><month>7</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p></license></permissions><abstract><sec><title>Objective</title><p>We tested the hypothesis that direct intramyocardial injection of bone marrow
mononuclear cells in patients with non-ischemic dilated cardiomyopathy can improve
left ventricular function and physical capacity.</p></sec><sec><title>Methods</title><p>Thirty non-ischemic dilated cardiomyopathy patients with left ventricular ejection
fraction &#x0003c;35% were randomized at a 1:2 ratio into two groups, control and
treated. The bone marrow mononuclear cells group received 1.06&#x000b1;108 bone marrow
mononuclear cells through mini-thoracotomy. There was no intervention in the
control group. Assessment was carried out through clinical evaluations as well as
a 6-min walk test, nuclear magnectic resonance imaging and echocardiogram.</p></sec><sec><title>Results</title><p>The bone marrow mononuclear cells group showed a trend toward left ventricular
ejection fraction improvement, with magnectic resonance imaging - at 3 months,
showing an increase from 27.80&#x000b1;6.86% to 30.13&#x000b1;9.06% (<italic>P</italic>=0.08) and
returning to baseline at 9 months (28.78%, <italic>P</italic>=0.77). Magnectic
resonance imaging showed no changes in left ventricular ejection fraction during
follow-up of the control group (28.00&#x000b1;4.32%, 27.42&#x000b1;7.41%, and 29.57&#x000b1;4.50%).
Echocardiogram showed left ventricular ejection fraction improved in the bone
marrow mononuclear cells group at 3 months, 25.09&#x000b1;3.98 to 30.94&#x000b1;9.16
(<italic>P</italic>=0.01), and one year, 30.07&#x000b1;7.25%
(<italic>P</italic>=0.001). The control group showed no change (26.1&#x000b1;4.4 vs
26.5&#x000b1;4.7 and 30.2&#x000b1;7.39%, <italic>P</italic>=0.25 and 0.10, respectively). Bone
marrow mononuclear cells group showed improvement in New York Heart Association
functional class, from 3.40&#x000b1;0.50 to 2.41&#x000b1;0.79 (<italic>P</italic>=0.002); patients
in the control group showed no change (3.37&#x000b1;0.51 to 2.71&#x000b1;0.95;
<italic>P</italic>=0.17). Six-minute walk test improved in the bone marrow
mononuclear cells group (348.00&#x000b1;93.51m at baseline to 370.41&#x000b1;91.56m at 12 months,
<italic>P</italic>=0.66) and there was a non-significant decline in the control
group (361.25&#x000b1;90.78m to 330.00&#x000b1;123.42m after 12 months, <italic>P</italic>=0.66).
Group comparisons were non-significant.</p></sec><sec><title>Conclusion</title><p>The trend of intragroup functional and subjective improvement was not confirmed
when compared to the control group. Direct intramyocardial application of bone
marrow mononuclear cells in non-ischemic dilated cardiomyopathy was not associated
with significant changes in left ventricular function. Differences observed within
the bone marrow mononuclear cells group could be due to placebo effect or low
statistical power.</p></sec></abstract><trans-abstract xml:lang="pt"><sec><title>Objetivo</title><p>Testamos a hip&#x000f3;tese de que a inje&#x000e7;&#x000e3;o intramioc&#x000e1;rdica direta de c&#x000e9;lulas
mononucleares de medula &#x000f3;ssea em pacientes portadores de cardiomiopatia dilatada
n&#x000e3;o-isqu&#x000ea;mica pode melhorar a fun&#x000e7;&#x000e3;o ventricular e a capacidade f&#x000ed;sica.</p></sec><sec><title>M&#x000e9;todos</title><p>Trinta pacientes com cardiomiopatia dilatada n&#x000e3;o isqu&#x000ea;mica e fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o 35%
foram randomizados na raz&#x000e3;o 1:2 em grupos controle e tratado. Grupo c&#x000e9;lulas
mononucleares de medula &#x000f3;ssea recebeu 1,06 &#x000b1; 108 c&#x000e9;lulas mononucleares de medula
&#x000f3;ssea por mini-toracotomia. Grupo controle n&#x000e3;o recebeu interven&#x000e7;&#x000e3;o. Avalia&#x000e7;&#x000e3;o foi
feita clinicamente e por teste de caminhada 6 minutos (T6m), resson&#x000e2;ncia magn&#x000e9;tica
e ecocardiogramas.</p></sec><sec><title>Resultados</title><p>Grupo c&#x000e9;lulas mononucleares de medula &#x000f3;ssea mostrou tend&#x000ea;ncia de melhora da Fra&#x000e7;&#x000e3;o
de eje&#x000e7;&#x000e3;o - resson&#x000e2;ncia magn&#x000e9;tica aos 3 meses, 27,80&#x000b1;6,86% para 30,13&#x000b1;9,06%
(<italic>P</italic>=0,08), retornando ao basal aos 9 meses (28,78%,
<italic>P</italic>=0,77). Grupo controle n&#x000e3;o apresentou varia&#x000e7;&#x000e3;o (28,00&#x000b1;4,32%;
27,42&#x000b1;7,41% e 29,57&#x000b1;4,50%). Ecocardiogramas - fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o melhorou no grupo
c&#x000e9;lulas mononucleares de medula &#x000f3;ssea aos 3 meses: 25,09&#x000b1;3,98 para 30,94&#x000b1;9,16
(<italic>P</italic>=0,01) e aos 12 meses (30,07&#x000b1;7,25%,
<italic>P</italic>=0,001), enquanto o controle n&#x000e3;o variou: 26,1&#x000b1;4,4
<italic>vs.</italic> 26,5&#x000b1;4,7 e 30,2&#x000b1;7,39%, <italic>P</italic>=0,25 e 0,10,
respectivamente). C&#x000e9;lulas mononucleares de medula &#x000f3;ssea melhorou classe funcional
<italic>New York Heart Association:</italic> 3,40&#x000b1;0.50 para 2,41&#x000b1;0,79
(<italic>P</italic>=0,002); controles n&#x000e3;o mudaram (3,37&#x000b1;0,51 para 2,71&#x000b1;0,95;
<italic>P</italic>=0,17). T6m melhorou no grupo c&#x000e9;lulas mononucleares de medula
&#x000f3;ssea (348,00&#x000b1;93,51 m inicial para 370,41&#x000b1;91,56 m aos 12 m,
<italic>P</italic>=0,66) e declinou sem signific&#x000e2;ncia no controle (361,25&#x000b1;90,78 m
para 330,00&#x000b1;123,42 m aos 12 meses, <italic>P</italic>=0,66). N&#x000e3;o houve diferen&#x000e7;as
significativas entre os grupos.</p></sec><sec><title>Conclus&#x000e3;o</title><p>A tend&#x000ea;ncia intragrupo de melhora funcional e subjetiva n&#x000e3;o se confirmou quando
comparado com controle. Portanto, a inje&#x000e7;&#x000e3;o direta intramioc&#x000e1;rdica de c&#x000e9;lulas
mononucleares de medula &#x000f3;ssea n&#x000e3;o se associou a mudan&#x000e7;a significativa na fun&#x000e7;&#x000e3;o
ventricular. As diferen&#x000e7;as observadas no grupo tratado poderiam ser devidas a
efeito placebo ou a baixo poder estat&#x000ed;stico.</p></sec></trans-abstract><kwd-group><kwd>Cardiomyopathy, Dilated</kwd><kwd>Heart Failure</kwd><kwd>Cells</kwd><kwd>Myocardial Contraction</kwd><kwd>Transplantation</kwd></kwd-group></article-meta></front><body><table-wrap id="t01" orientation="portrait" position="float"><table frame="box" rules="groups"><thead><tr><th colspan="2" align="left" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">BMMC</td><td rowspan="1" colspan="1">Bone marrow mononuclear cells</td></tr><tr><td rowspan="1" colspan="1">DCM</td><td rowspan="1" colspan="1">Dilated cardiomyopathy</td></tr><tr><td rowspan="1" colspan="1">LVEF</td><td rowspan="1" colspan="1">Left ventricular ejection fraction</td></tr><tr><td rowspan="1" colspan="1">MLHF</td><td rowspan="1" colspan="1">Minnesota Living with Heart Failure</td></tr><tr><td rowspan="1" colspan="1">MRI</td><td rowspan="1" colspan="1">Magnetic resonance cardiac imaging</td></tr><tr><td rowspan="1" colspan="1">NIDCM</td><td rowspan="1" colspan="1">Non-ischemic dilated cardiomyopathy</td></tr><tr><td rowspan="1" colspan="1">NYHA</td><td rowspan="1" colspan="1">New York Heart Association</td></tr><tr><td rowspan="1" colspan="1">PO</td><td rowspan="1" colspan="1">Post-operatively</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Dilated cardiomyopathy is a leading cause of heart failure and the primary indication
for heart transplantation<sup>[<xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>]</sup>. The prevalence of this disease tends to
increase according to population ageing and survival improvement achieved through
advances in pharmacological treatment and implantable devices<sup>[<xref rid="r03" ref-type="bibr">3</xref>]</sup>. However, current therapeutic approaches are palliative
in the sense that they are unable to directly address the underlying problem of the loss
of cardiac tissue<sup>[<xref rid="r04" ref-type="bibr">4</xref>]</sup>.</p><p>Cell therapy with bone marrow mononuclear cells (BMMC) has been associated with
beneficial effects in patients with acute myocardial infarction and ischemic heart
failure. Data for non-ischemic dilated cardiomyopathy (NIDCM), however, is more
limited<sup>[<xref rid="r05" ref-type="bibr">5</xref>-<xref rid="r07" ref-type="bibr">7</xref>]</sup>. Experimental studies suggest that stem cells improve
heart function through both paracrine regulation of cytokines production and cell
transdifferentiation, albeit in a small proportion of the transplanted cells<sup>[<xref rid="r08" ref-type="bibr">8</xref>,<xref rid="r09" ref-type="bibr">9</xref>]</sup>. Two small trials, using BMMC through intracoronary route, showed
small, but significant increase in left ventricular ejection fraction (LVEF) after
treatment<sup>[<xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref>]</sup>. Recently, intracoronary injection of CD34+ was
associated with medium-term improvement of ventricular function, exercise tolerance, and
long-term survival in randomized trial of patients with DCM<sup>[<xref rid="r07" ref-type="bibr">7</xref>]</sup>.</p><p>Intracoronary injection is associated with a small percentage of transplanted cells
effectively retained in the myocardium, which could limit results when that route is
used for cell therapy<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. In a pilot
study, we found that direct application of BMMC through a small thoracotomy was safe and
associated with a significant, although transitory, increase in LVEF in patients with
non-ischemic dilated cardiomyopathy (NIDCM)<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. In the present study, we tested the hypothesis that direct
intramyocardial injection of BMMC in patients with NIDCM could improve LVEF assessed by
cardiac magnetic resonance imaging (MRI) and echocardiogram, physical capacity evaluated
by the six-minute walk test (6WT), and heart failure class functional (NYHA), when
compared to conventional treatment.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study design</title><p>We conducted an open, parallel-group, explanatory randomized study in a single center
to evaluate the safety and efficacy of BMMC in patients NIDCM. Thirty patients that
fulfilled the criteria for inclusion were randomly assigned to each of the groups by
means of a computer software for simple randomization: BMMC or control, in a 2:1
proportion.</p><p>After randomization, functional status of both groups was assessed at baseline using
(6WT), New York Heart Association (NYHA) and Minnesota Living with Heart Failure
(MLHF) questionnaires, which had been previously validated for the Brazilian
population<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. We used
cardiac magnetic resonance imaging (MRI) to measure left ventricular diameters and
ejection fraction. Functional status was reassessed every three months and MRI
repeated three and nine months after inclusion. All patients were treated by the same
physician at a dedicated outpatient clinic, according to ACC/AHA Guidelines for the
Diagnosis and Management of Heart Failure in Adults<sup>[<xref rid="r01" ref-type="bibr">1</xref>]</sup>. Functional status was evaluated by a separate team.
In this article, we present the results of the first year of follow-up. We were
unable to perform a blind study because of the invasive nature of the procedure
proposed. The study was submitted to the National Comission in Research (CONEP) and
approved. All patients signed an informed consent.</p><p>Patients in the BMMC group, in addition to conventional treatment, were submitted to
BMMC transplantation as described below up to one month after randomization. In this
group, we also conducted flow citometry and imunohistochemistry to characterize bone
marrow cells.</p><p>Our primary objective was to evaluate changes in left ventricular ejection fraction
assessed with MRI. Secondary objectives consisted of evaluation of: 1) Safety; 2) New
York Heart Association (NYHA) functional class and quality of life measured with
Minnesota Living with Heart Failure Questionnaire; 3) Effects in mortality; 4) Left
ventricular diameters using MRI.</p></sec><sec><title>Inclusion and exclusion criteria</title><p>The study was approved by the Ethics Review Board of Instituto de Cardiologia do Rio
Grande do Sul/ Funda&#x000e7;&#x000e3;o Universit&#x000e1;ria de Cardiologia (IC/FUC), as well as by the
National Ethics Committee in Research of Brazil, under protocol number 10376 and
registered in ClinicalTrials.gov under number: NCT00743639. Both the study and the
registry were conducted in accordance with the Declaration of Helsinki. Written
informed consent was obtained from each patient.</p><p>We screened for patients with heart failure, LVEF less then 35% and functional class
III or IV, despite full medical treatment. Specific inclusion criteria were: (1) Age
between 20 and 65 years; (2) Diagnosis of non-ischemic cardiomyopathy for at least 12
months before enrollment; (3) Coronary angiography with normal coronary arteries,
which defined cardiomyopathy as non-ischemic for the purposes of this trial; (4)
negative serology for Chagas Disease; and (5) Absence of other significant systemic
disease limiting mid-term prognosis. We excluded patients with: (1) Documented
episodes of ventricular tachycardia; (2) Moderate to severe mitral regurgitation or
any other significant valve disease; (3) History of myocardial infarction; and (4)
Previous cardiac surgery.</p></sec><sec><title>Bone marrow mononuclear cells isolation and transplantation</title><p>Approximately four hours before the operation and with the patient under sedation, a
volume of about 80 mL of bone marrow was aspirated from the anterior iliac crest and
placed in an anticoagulated medium. Mononuclear cell fraction was separated by
density centrifugation over Ficoll-Hypaque-1077 (Sigma Diagnostics, St Louis, MO) and
washed in a heparinized saline solution containing 5% autologous serum. Cells were
counted and suspended in 5 mL saline solution for intramyocardial injection. A small
fraction was utilized for sterility and viability tests and for immunophenotyping.
Viability greater than 90% was considered acceptable.</p><p>For detection of surface antigens the cells were trypsinized, centrifuged, and
incubated for 30 minutes at 4&#x000b1;C with phycoerythrin (PE)- or fluorescein
isothiocyanate (FITC)-conjugated antibodies against human CD3, CD4, CD14, CD34, CD38
and CD45 (Pharmingen BD, San Diego, CA). Excess antibody was removed by washing. The
cells were analyzed using a FACScalibur cytometer equipped with 488 nm argon laser
(Becton Dickinson, San Diego, CA) with the CellQuest software. At least 10,000 events
were collected. WinMDI 2.8 software was used for building histograms.</p><p>Surgical approach was through a left mini-thoracotomy, consisting of an approximately
5 cm incision in the anterolateral portion of the fifth left intercostal space to
expose the pericardium. A T-shaped pericardial incision was made to access the free
wall of the left ventricle. Coronary arteries were identified and the cell suspension
was directly injected, using a 21F Butterfly needle that was introduced about 5mm
intramyocardially and connected to an extension managed by the surgical assistant.
Twenty 0.25 mL injections were given in the myocardium and in the anterior, lateral,
posterior, and apical faces of the left ventricular free wall. After reviewing the
hemostasis, pericardium was approximated, the thoracic cavity was drained and the
chest wall closed.</p></sec><sec><title>Echocardiogram</title><p>Two-dimensional echocardiograms were obtained for measuring end-systolic volume
(ESV), end-diastolic volume (EDV), and LVEF, according to standard protocols. All
exams were performed by the same person, who was unaware of the treatment group and
was not part of the study team. It should be noted, however, that treated patients
had a visible scar in the left chest, which made it impossible to guarantee blindness
to the echo examinator.</p></sec><sec><title>Magnetic Resonance Imaging</title><p>All MRI image analyses were performed by the same investigator, which was blind to
the assignment of the patient. We used a 1.5-T scanner (GE Excite HDx) with ECG
gating and a 4-element phased-array surface coil. Scan planes were planned according
to standard procedures. Endocardial and epicardial borders were traced in all
end-diastolic and end-systolic short-axis slices to determine LV end-diastolic and
end-systolic volumes (LVEDV and LVESV). Global LVEF was calculated
[(LVEDV-LVESV)/LVEDV]/100 LVEDV. Systolic ventricular wall thickening was calculated
for different heart segments and it was used for an already published
sub-study<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p></sec><sec><title>Statistical analysis</title><p>Continuous variables are presented as mean&#x000b1;SD, if not stated otherwise. Categorical
variables were compared with the x<sup>2</sup> test or Fisher's exact test.
Statistical comparisons between initial and follow-up data were performed in a
nonparametric paired fashion using the Wilcoxon signed rank test. Nonparametric
Mann-Whitney U and Kruskal-Wallis tests were used to compare continuous and
categorical variable, as well as the results between different groups. All tests were
performed as 2-sided tests at a significance level of 0.05.</p><p>In the first three months of follow-up, 25% of the patients from the BMMC group had
either died or been withdrawn from the study, resulting in a decrease in the number
of treated cases available for late follow-up. Since those patients had a lower mean
ejection fraction than the whole group (18.26 % <italic>vs.</italic> 21.75%), we
excluded them from comparative analysis, in order to avoid overestimation of
treatment effect. In other words, outcome analysis was performed in as-treated basis,
not as intention-to-treat.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Baseline</title><p>Baseline characteristics are detailed in <xref ref-type="table" rid="t02">Table
1</xref>. There were no significant differences in baseline data between BMMC and
control groups. All patients had severe heart failure and were highly symptomatic by
the time of inclusion, despite maximum medical therapy.</p><table-wrap id="t02" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline patients characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">BMMC group</th><th rowspan="1" colspan="1">Control group</th></tr><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">(n=20)</th><th rowspan="1" colspan="1">(n=10)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">13 (65%)</td><td align="center" rowspan="1" colspan="1">5 (50%)</td></tr><tr><td rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">48.3 (8.71)</td><td align="center" rowspan="1" colspan="1">51.6 (7.79)</td></tr><tr><td rowspan="1" colspan="1">NYHA class</td><td align="center" rowspan="1" colspan="1">3.5 (0.52)</td><td align="center" rowspan="1" colspan="1">3.35 (0.48)</td></tr><tr><td rowspan="2" colspan="1"> Minnesota QOL score (Minnesota)</td><td align="center" rowspan="1" colspan="1">66.2 (22.46)</td><td align="center" rowspan="1" colspan="1">50.6 (14.84)</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Six minute walk test (min)</td><td align="center" rowspan="1" colspan="1">358.5 (88.69)</td><td align="center" rowspan="1" colspan="1">353 (86.67)</td></tr><tr><td rowspan="1" colspan="1">LVEF by ECHO (%)</td><td align="center" rowspan="1" colspan="1">21.75 (41.19)</td><td align="center" rowspan="1" colspan="1">24.76 (4.64)</td></tr><tr><td rowspan="1" colspan="1">Final diastolic diameter, ECHO (mm)</td><td align="center" rowspan="1" colspan="1">73.4 (8.18)</td><td align="center" rowspan="1" colspan="1">70.3 (7.4)</td></tr><tr><td rowspan="1" colspan="1">LVEF by MRI (%)</td><td align="center" rowspan="1" colspan="1">27.80&#x000b1;6.86</td><td align="center" rowspan="1" colspan="1">28.00&#x000b1;4.32</td></tr><tr><td rowspan="1" colspan="1">N&#x000ba; of injected cells</td><td align="center" rowspan="1" colspan="1">1.06 x 10<sup>8</sup></td><td align="center" rowspan="1" colspan="1">none</td></tr></tbody></table><table-wrap-foot><fn><p>Data expressed as mean (% or SD);</p></fn><fn><p>LVEF by ECHO=left ventricular ejection fraction by echocardiogram;
MRI=nuclear magnetic resonance imaging; QOL=quality of life by Minnesota
Living with Heart Failure Questionnaire. There were no statistically
significant differences between baseline groups characteristics</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Cell analysis</title><p>A mean of 1.06&#x000b1;0.43 x 10<sup>8</sup> mononuclear cells per patient were available for
injection using this method. Cell viability was greater than 99%, and fungal and
bacterial cultures were negative.</p><p>Cells from the first five samples were analyzed in greater detail. Immunophenotyping
of the mononuclear cell fraction showed the following composition: CD34+ cells
(1.5&#x000b1;0.7%), CD45+ (74.6&#x000b1;8.5%), CD14+ (8.4&#x000b1;4.7%), CD3+CD4+ (22.8&#x000b1;4.6%), CD3+CD8+
(8.2&#x000b1;6.1%), and CD34+CD38- cells (0.7&#x000b1;0.5%).</p></sec><sec><title>Procedural safety and clinical outcomes</title><p>Surgical procedure was effectively performed in 19 patients, since one patient asked
to be withdrawn soon after randomization. <xref ref-type="table" rid="t03">Table
2</xref> summarizes surgical results. Four subjects died in the first month after
the procedure. Two died of refractory cardiogenic shock in the first 72 hours
post-operatively (PO). One of them presented with cardiac tamponade 7 hours after
surgery and was submitted to reoperation. The patient's hemodynamic condition
continued to deteriorate and he died due to cardiogenic shock 3 days PO. Another
patient died on the 15<sup>th</sup> day PO due to incessant ventricular tachycardia.
Finally, one patient died on the 28<sup>th</sup> day PO: he had been discharged from
hospital, but was readmitted one week later due to heart failure, which was
refractory to treatment. All of the patients above had LVEF below 21% before
operation.</p><table-wrap id="t03" orientation="portrait" position="float"><label>Table 2</label><caption><p>Surgical results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Surgery</th><th rowspan="1" colspan="1">Mean &#x000b1;DP</th><th rowspan="1" colspan="1">Max value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Thoracotomy procedure (min)</td><td align="center" rowspan="1" colspan="1">84.7&#x000b1;29</td><td align="center" rowspan="1" colspan="1">120</td></tr><tr><td rowspan="1" colspan="1">Post-operative, %</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Length of ICU Stay (days)</td><td align="center" rowspan="1" colspan="1">1.86&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">Length of hospital stay (days)</td><td align="center" rowspan="1" colspan="1">4.50&#x000b1;2.0</td><td align="center" rowspan="1" colspan="1">9</td></tr></tbody></table></table-wrap><p>Three patients from the BMMC group died between 30 days and 12 months after surgery.
In two patients, death was sudden, at 10 and 11 months PO. Another patient died 6
months PO due to heart failure.</p><p>In the control group, one patient died three months after randomization due to heart
failure and another patient was lost for follow-up two months after randomization.
There was no statistically significant difference in safety outcomes between BMMC and
control groups: Fischer's test showed no difference in mortality between groups in
the first 30 days (<italic>P</italic>=0.371) or up to 12 months
(<italic>P</italic>=1.000).</p></sec><sec><title>Effects of BMMC on LV Function</title><sec><title>MRI evaluations</title><p>Patients of the BMMC group maintained LVEF at 3 months, from 27.80&#x000b1;6.86% to
30.13&#x000b1;9.06% (<italic>P</italic>=0.08), and at 9 months (28.78%,
<italic>P</italic>=0.77). The control group also maintained systolic function
during follow-up (28&#x000b1;4.32% <italic>vs.</italic> 27.4&#x000b1;7.4%, at 3 months,
<italic>P</italic>=0.79, and <italic>vs.</italic> 29.57&#x000b1;4.50 at 9 months,
<italic>P</italic>=0.46, respectively). Differences between groups were
non-significant.</p><p>Both groups maintained end-systolic and end-diastolic volumes during follow-up.
(<xref ref-type="table" rid="t04">Table 3</xref>).</p><table-wrap id="t04" orientation="portrait" position="float"><label>Table 3</label><caption><p>Left ventricular volumes and function as assessed by Magnetic Resonance
Imaging (MRI).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th rowspan="1" colspan="1">BMMC group</th><th rowspan="1" colspan="1">Control group</th><th rowspan="1" colspan="1"><italic>P</italic></th></tr><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">(n = 15)</th><th rowspan="1" colspan="1">(n=9)</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Ejection Fraction, %</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">27.80&#x000b1;6.86</td><td align="center" rowspan="1" colspan="1">28.00&#x000b1;4.32</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">30.13&#x000b1;9.06</td><td align="center" rowspan="1" colspan="1">27.42&#x000b1;7.41</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">2.33</td><td align="center" rowspan="1" colspan="1">-0.58</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P </italic>value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">0.79</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">9 months</td><td align="center" rowspan="1" colspan="1">28.78&#x000b1;9.97</td><td align="center" rowspan="1" colspan="1">29.57&#x000b1;4.50</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">+1.57</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P </italic>value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.77</td><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">End-diastolic volume, mL</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">272.73&#x000b1;63.41</td><td align="center" rowspan="1" colspan="1">250.85&#x000b1;67.00</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">264.86&#x000b1;72.24</td><td align="center" rowspan="1" colspan="1">222.42&#x000b1;96.19</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-7.87</td><td align="center" rowspan="1" colspan="1">-28.43</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.41</td><td align="center" rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">9 months</td><td align="center" rowspan="1" colspan="1">258.64&#x000b1;82.97</td><td align="center" rowspan="1" colspan="1">258.85&#x000b1;75.55</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-14.09</td><td align="center" rowspan="1" colspan="1">+8.00</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">0.71</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">End-svstolic volume, mL</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">200.40&#x000b1;61.59</td><td align="center" rowspan="1" colspan="1">182.00&#x000b1;55.70</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">195.93&#x000b1;78.49</td><td align="center" rowspan="1" colspan="1">161.67&#x000b1;67.83</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-4.47</td><td align="center" rowspan="1" colspan="1">- 20.43</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.66</td><td align="center" rowspan="1" colspan="1">0.18</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">9 months</td><td align="center" rowspan="1" colspan="1">190.00&#x000b1;82.18</td><td align="center" rowspan="1" colspan="1">184.14&#x000b1;58.55</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-10.40</td><td align="center" rowspan="1" colspan="1">2.14</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.73</td><td align="center" rowspan="1" colspan="1">0.91</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap></sec><sec><title>Echocardiographic evaluations</title><p>Patients of the BMMC group had a significant improvement in left ventricular
ejection fraction 3 months after the procedure, from 25.09&#x000b1;3.98 to 30.94&#x000b1;9.16
(<italic>P</italic>=0.01). This benefit was maintained after one year of
follow-up (30.07&#x000b1;7.25, <italic>P</italic>=0.001). The control group has showed no
change in the same period (26.1&#x000b1;4.4 <italic>vs.</italic> 26.5&#x000b1;4.7 and 30.2&#x000b1;7.39,
<italic>P</italic>=0.25 and 0.10, respectively). Differences between treated
and control groups, however, were not statistically significant. Left ventricular
fractional shortening evaluation showed similar results. End-systolic and
end-diastolic diameters had a small reduction in both groups. (<xref ref-type="fig" rid="f01">Figure 1</xref>, <xref ref-type="table" rid="t05">Table 4</xref>).</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><p>A) Left ventricular ejection fraction and B) end-systolic diameter by
echocardiography at baseline and during follow-up</p></caption><graphic xlink:href="rbccv-29-03-0437-g01"/></fig><table-wrap id="t05" orientation="portrait" position="float"><label>Table 4</label><caption><p>Left ventricular volumes and function as assessed by echocardiography
(ECO).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th rowspan="1" colspan="1">BMMC group</th><th rowspan="1" colspan="1">Control group</th><th rowspan="1" colspan="1"><italic>P</italic></th></tr><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">(n = 15)</th><th rowspan="1" colspan="1">(n=9)</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Ejection Fraction, %</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">25.09&#x000b1;3.98</td><td align="center" rowspan="1" colspan="1">26.10 &#x000b1; 4.49</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">28.11&#x000b1;7.22</td><td align="center" rowspan="1" colspan="1">26.525 &#x000b1; 4.71</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">3.02</td><td align="center" rowspan="1" colspan="1">0.425</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P </italic>value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">0.628</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">30.94&#x000b1;9.16</td><td align="center" rowspan="1" colspan="1">28.51 &#x000b1; 6.98</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">5.85</td><td align="center" rowspan="1" colspan="1">2.41</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">P value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.250</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">30.07&#x000b1;7.25</td><td align="center" rowspan="1" colspan="1">30.23&#x000b1;7.39</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">4.98</td><td align="center" rowspan="1" colspan="1">4.13</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P </italic>value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.100</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">End-diastolic diameter, mm</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">69.80&#x000b1;4.41</td><td align="center" rowspan="1" colspan="1">69.375&#x000b1;7.81</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">68.33&#x000b1;6.38</td><td align="center" rowspan="1" colspan="1">68.62&#x000b1;8.39</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-1.47</td><td align="center" rowspan="1" colspan="1">0.75</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P </italic>value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.18</td><td align="center" rowspan="1" colspan="1">0.170</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">68.28&#x000b1;6.48</td><td align="center" rowspan="1" colspan="1">69.85&#x000b1;9.66</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-1.52</td><td align="center" rowspan="1" colspan="1">0.479</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P </italic>value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.27</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">68.66&#x000b1;7.35</td><td align="center" rowspan="1" colspan="1">68.28&#x000b1;8.47</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-1.14</td><td align="center" rowspan="1" colspan="1">-1.09</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P </italic>value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.49</td><td align="center" rowspan="1" colspan="1">0.612</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">End-svstolic diameter, mm</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">61.46&#x000b1;4.65</td><td align="center" rowspan="1" colspan="1">60.75&#x000b1;7.86</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">60.33&#x000b1;7.64</td><td align="center" rowspan="1" colspan="1">60.00&#x000b1;8.28</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-1.13</td><td align="center" rowspan="1" colspan="1">-0.75</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P </italic>value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.47</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">58.14&#x000b1;8.12</td><td align="center" rowspan="1" colspan="1">60.42&#x000b1;9.98</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-3.32</td><td align="center" rowspan="1" colspan="1">-0.33</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P </italic>value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">58.83&#x000b1;8.50</td><td align="center" rowspan="1" colspan="1">58.42&#x000b1;9.10</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-2.63</td><td align="center" rowspan="1" colspan="1">-2.33</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P </italic>value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.17</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap></sec></sec><sec><title>Quality of life and 6-minute walk test</title><p>Quality of life, evaluated by MLHFQ (Minnesota Living with Heart Failure
Questionnaire), improved significantly in the BMMC group three months after the
procedure (69.00&#x000b1;20.71 <italic>vs.</italic> 43.13&#x000b1;27.92 points,
<italic>P</italic>=0.005), a benefit maintained during 6 and 12 months of follow-up
(48.92&#x000b1;24.26 points, <italic>P</italic>=0.018; 37.08&#x000b1;21.15 points,
<italic>P</italic>=0.001; respectively). Patients of the control group showed a
non-significant improvement, with smaller differences between baseline and 12 months
follow-up (minus 31.92 points for BMMC group and minus 7.16 points for Control
group). Differences between groups were not statistically significant. Functional
class, evaluated using NYHA Classification, showed similar results with a
statistically significant improvement in the BMMC group, no change in the control
group. However, once again, there were no statistically significant differences
between groups. (<xref ref-type="fig" rid="f02">Figure 2</xref>, <xref ref-type="table" rid="t06">Table 5</xref>).</p><fig id="f02" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>A) Quality-of-Life score (Minnesota), B) Six-minute walk test and C) NYHA
Functional class at baseline and during follow-up</p></caption><graphic xlink:href="rbccv-29-03-0437-g02"/></fig><table-wrap id="t06" orientation="portrait" position="float"><label>Table 5</label><caption><p>Minnesota Living with Heart Failure Questionnaire, New York Heart Association
Functional Class and 6-Minutes-Walk Test results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th rowspan="1" colspan="1">BMMC group</th><th rowspan="1" colspan="1">Control group</th><th rowspan="1" colspan="1"><italic>P</italic></th></tr><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">(n = 15)</th><th rowspan="1" colspan="1">(n=9)</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Minnesota LHFQ</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">69.00&#x000b1;20.71</td><td align="center" rowspan="1" colspan="1">48.87&#x000b1;16.32</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">43.13&#x000b1;27.92</td><td align="center" rowspan="1" colspan="1">54.37&#x000b1;23.71</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-25.87</td><td align="center" rowspan="1" colspan="1">+5.50</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">0.57</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">48.92&#x000b1;24.26</td><td align="center" rowspan="1" colspan="1">40.28&#x000b1;23.59</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-20.08</td><td align="center" rowspan="1" colspan="1">-8.58</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">0.31</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">37.08&#x000b1;21.15</td><td align="center" rowspan="1" colspan="1">41.71&#x000b1;27.46</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-31.92</td><td align="center" rowspan="1" colspan="1">-7.16</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">6-minutes-walk test</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">348.00&#x000b1;93.51</td><td align="center" rowspan="1" colspan="1">361.25&#x000b1;90.78</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">338.66&#x000b1;116.48</td><td align="center" rowspan="1" colspan="1">336.25&#x000b1;114.38</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-9.34</td><td align="center" rowspan="1" colspan="1">- 25</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.73</td><td align="center" rowspan="1" colspan="1">0.44</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">355.35&#x000b1;67.77</td><td align="center" rowspan="1" colspan="1">365.00&#x000b1;126.45</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">7.35</td><td align="center" rowspan="1" colspan="1">3.75</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.81</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">370.41&#x000b1;91.56</td><td align="center" rowspan="1" colspan="1">330.00&#x000b1;123.42</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">22.41</td><td align="center" rowspan="1" colspan="1">-31.25</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.66</td><td align="center" rowspan="1" colspan="1">0.39</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">NYHA</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">3.40&#x000b1;0.50</td><td align="center" rowspan="1" colspan="1">3.37&#x000b1;0.51</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">2.60&#x000b1;0.82</td><td align="center" rowspan="1" colspan="1">3.00&#x000b1;0.75</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-0.8</td><td align="center" rowspan="1" colspan="1">- 0.37</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">0.19</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">2.50&#x000b1;0.75</td><td align="center" rowspan="1" colspan="1">2.57&#x000b1;0.78</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-0.9</td><td align="center" rowspan="1" colspan="1">-0.8</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">2.41&#x000b1;0.79</td><td align="center" rowspan="1" colspan="1">2.71&#x000b1;0.95</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Change from baseline</td><td align="center" rowspan="1" colspan="1">-0.99</td><td align="center" rowspan="1" colspan="1">- 0.66</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1"><italic>P</italic> value comparing to baseline</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">0.17</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><p>Six-minute-walk test results were maintained in the BMMC group (from 348.00&#x000b1;93.51min
in baseline to 370.41&#x000b1;91.56 min after 12 months, <italic>P</italic>=0.66) and in
control group (from 361.25&#x000b1;90.78 min in baseline to 330.00&#x000b1;123.42 min after 12
months, <italic>P</italic>=0.66). Again, differences between groups were not
statistically significant. (<xref ref-type="table" rid="t06">Table 5</xref>).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this study, we tested the hypothesis that transplantation of BMMC through a small
thoracotomy could improve left ventricular function in patients with refractory heart
failure due to NIDCM. Our main findings were: (1) Mortality associated with the
procedure was directly related to preoperative disease severity. In particular, patients
with LVEF below 21% had a poor surgical result. Early deaths were related to
postoperative pump-failure and congestive heart failure, while deaths at medium term
were sudden, probably caused by cardiac arrhythmias. These results differ from our
previous pilot study, in which there had been no deaths<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. (2) Survivors treated with BMMC maintained left
ventricular function relative to baseline according to MRI. (3) Overall, patients had
symptomatic improvement during follow-up, which was more pronounced in the BMMC group,
but there was no statistical difference between groups in the outcomes studied.</p><p>The seven deaths (35%) observed in patients who received BMMC were due to pump-failure
in the early post-operative period (2 cases; 28.5%), congestive heart failure (2 cases,
28.5%) and documented ventricular arrhythmia or sudden death (3 cases, 42.8%). Using the
Seattle Heart Failure Model, a tool with excellent accuracy for predicting survival
among patients with heart failure<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>,
we could anticipate one-year mortality between 20% and 25%. Incidence of death
attributable to arrhythmia (42,8%) was higher than expected for patients in NYHA
functional class III (10.5%) or IV (18.6%) at one year<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>This higher than expected risk of ventricular tachyarrhythmia after surgery could be
related to the intrinsic high risk of any procedure in patients with severe heart
failure or to a more specific mechanism secondary to BMMC injection. Stem cell
pro-arrhythmic potential is a matter of intense debate<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>. Clinically,
bone marrow progenitor cells were not associated with increased risk of arrhythmias
using different routes of delivery in different clinical scenarios<sup>[<xref rid="r17" ref-type="bibr">17</xref>-<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Yet, experimental studies have shown that mesenchymal stem cells
(MSCs) implantation altered cardiac conduction<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> and created areas of slow conduction, predisposing it to reentry
episodes<sup>[<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r22" ref-type="bibr">22</xref>]</sup>. Intramyocardial injections can create clusters of
cells leading to heterogeneity in conduction and have been associated with greater risk
of ventricular premature complexes than intracoronary injection<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. How this translates into clinical
practice, where patients are treated with anti-arrhythmic drugs, needs to be further
clarified. At this point, however, we cannot dismiss the possibility of a pro-arrhythmic
effect related the newly implanted cells.</p><p>BMMC treated patients who survived for more than one month after the procedure showed
significant improvements in both symptoms and quality of life. Left ventricular ejection
fraction was maintained one year after the procedure (<italic>P</italic>=0.77). Results
with echocardiography are more pronounced as they showed improvement in LVEF of patients
treated with BMMC after 6 months (from 25.09&#x000b1;3.98 to 30.94&#x000b1;9.16,
<italic>P</italic>=0.01). Nevertheless, since operators were not blind for patients'
group, results from this method should be interpreted with caution.</p><p>Clinical experience with mononuclear cells in patients with DCM is limited.
Fischer-Rasokat et al performed infusion of BMMC in 33 patients with DCM using an
over-the-wire balloon catheter in the left descending coronary artery<sup>[<xref rid="r08" ref-type="bibr">8</xref>]</sup>. After 3 months, regional wall motion of
the target area and global left ventricular ejection fraction had a small (about 10%)
but statistically significant improvement. Increase of regional contractile function was
directly related to the functionality of infused cells as measured by their
colony-forming capacity. Safety data was remarkably good, with no procedure related
complications and no deaths, stroke or myocardial infarction up to one year follow-up.
Compared to our study, patients were less symptomatic (67% in NYHA class II) and had
better ventricular function (mean LEVF=0.2%).</p><p>Vrtovec et al.<sup>[<xref rid="r07" ref-type="bibr">7</xref>]</sup> conducted a study
with 110 patients with NIDCM, which were randomized to receive CD34+ stem cell
transplantation and 55 received no cell therapy. Patients underwent myocardial
scintigraphy and cells were injected in the artery supplying segments with the greatest
perfusion defect. At 5 years, stem cell therapy was associated with increased LVEF (from
24.3&#x000b1;6.5% to 30.0&#x000b1;5.1%; <italic>P</italic>=0.02), increased 6-minute walk distance (from
344&#x000b1;90 m to 477&#x000b1; 30 m; <italic>P</italic>&#x0003c;0.001), and decreased N-terminal B-type
natriuretic peptide (from 2322&#x000b1;1234 pg/mL to 1011&#x000b1;893 pg/mL;
<italic>P</italic>&#x0003c;0.01). Left ventricular ejection fraction improvement was more
significant in patients with higher myocardial homing of injected cells. Total mortality
was lower in patients treated with CD 34+ cells (14% <italic>vs.</italic> 35%;
<italic>P</italic>=0.01) and the procedure was considered safe, with low
morbimortality.</p><p>Several limitations of our study are recognized. First: the trial was projected with a
small sample that was further reduced due to early mortality. This drawback was
unexpected, since we had no early major complications or mortality in a previous safety
study<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. High mortality could
be attributed to very low LVEF, which expressed extremely deteriorated LV function in
those patients who died early. There was no low LVEF limitation for patient inclusion in
the trial: all patients with LVEF&#x0003c;35% were candidates. Perhaps we could have avoided
including patients with very low LVEF (for example, LVEF&#x0003c;25%) or, alternatively, once
they were included, we could have employed special measures of support during and after
treatment. Besides, since observed increments in contractility reported on several
studies with cell therapy are small (in the range of 5 to 10%), the clinical impact of a
small increase in heart function in a very ill population may be negligible. Due to
these reasons, we can conclude that, in further studies, patients with LVEF&#x0003c;25%
should be avoided. Secondly, we opted to analyze data by protocol instead of intention
to treat, since patients who died had lower LVEF and maintaining their baseline data
would have overestimated treatment effect. Thirdly, this was a non-blinded trial: it is
possible that differences observed in quality of life and functional class could be due
to placebo effect. Results from the 6-minute walk test would have been useful to assess
more objectively functional capacity, but they were highly variable among patients,
creating high values of standard deviation that precluded an appropriate analysis.
Finally, high dispersion of data, from a wide range of parameters, such as LVEF and LV
diameters, resulted in increased standard deviations in most outcome parameters, which
in this small sample could have also precluded achievement of statistically significant
differences between groups.</p><p>In conclusion, besides intragroup improvement in echocardiographic data, quality of life
and NYHA class, when compared to control direct intramyocardial application of BMMC in
NIDCM was not associated with sustained significant changes in left ventricular
function. Functional capacity did not differ between groups. In future studies, less
invasive forms of cell transplantation should be evaluated considering the high
mortality observed, particularly for patients with severely impaired LVEF.</p><table-wrap id="t07" orientation="portrait" position="float"><table frame="box" rules="groups"><thead><tr><th colspan="2" align="left" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">RTSA</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data, statistical analysis, final
approval of the manuscript, conception and design of the study, realization
of operations and/or experiments, drafting of the manuscript and critical
review of the content</td></tr><tr><td rowspan="1" colspan="1">JF</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data, realization of operations and/or
experiments</td></tr><tr><td rowspan="1" colspan="1">FHV</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data, statistical analysis, final
approval of the manuscript conception and design of the study, realization
of operations and/or experiments,</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">Drafting of the manuscript and critical review of the content</td></tr><tr><td rowspan="1" colspan="1">IC</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data, realization of operations and/or
experiments</td></tr><tr><td rowspan="1" colspan="1">NBN</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data, statistical analysis, final
approval of the manuscript, realization of operations and/or
experiments</td></tr><tr><td rowspan="1" colspan="1">JRMSA</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data, realization of operations and/or
experiments</td></tr><tr><td rowspan="1" colspan="1">IAN</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data, final approval of the manuscript
conception and design of the study, realization of operations and/or
experiments</td></tr><tr><td rowspan="1" colspan="1">RAKK</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data, statistical analysis, final
approval of the manuscript conception and design of the study, realization
of operations and/or experiments, drafting of the manuscript and critical
review of the content</td></tr></tbody></table></table-wrap></sec></body><back><ref-list><title>REFERENCES</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>SA</given-names></name><name><surname>Abraham</surname><given-names>WT</given-names></name><name><surname>Chin</surname><given-names>MH</given-names></name><name><surname>Feldman</surname><given-names>AM</given-names></name><name><surname>Francis</surname><given-names>GS</given-names></name><name><surname>Ganiats</surname><given-names>TG</given-names></name><etal>et al</etal></person-group><article-title>2009 focused update incorporated into the ACC/AHA 2005 Guidelines for
the Diagnosis and Management of Heart Failure in Adults: a report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines: developed in collaboration with the International Society for Heart
and Lung Transplantation</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>14</issue><fpage>e391</fpage><lpage>e479</lpage><pub-id pub-id-type="pmid">19324966</pub-id></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manolio</surname><given-names>TA</given-names></name><name><surname>Baughman</surname><given-names>KL</given-names></name><name><surname>Rodeheffer</surname><given-names>R</given-names></name><name><surname>Pearson</surname><given-names>TA</given-names></name><name><surname>Bristow</surname><given-names>JD</given-names></name><name><surname>Michels</surname><given-names>VV</given-names></name><etal>et al</etal></person-group><article-title>Prevalence and etiology of idiopathic dilated cardiomyopathy (summary
of a National Heart, Lung, and Blood Institute workshop</article-title><source>Am J Cardiol</source><year>1992</year><volume>69</volume><issue>17</issue><fpage>1458</fpage><lpage>1466</lpage><pub-id pub-id-type="pmid">1590237</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubo</surname><given-names>T</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Kitaoka</surname><given-names>H</given-names></name><name><surname>Okawa</surname><given-names>M</given-names></name><name><surname>Hirota</surname><given-names>T</given-names></name><name><surname>Hamada</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Improvement in prognosis of dilated cardiomyopathy in the elderly over
the past 20 years</article-title><source>J Cardiol</source><year>2008</year><volume>52</volume><issue>2</issue><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">18922384</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd-Jones</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>R</given-names></name><name><surname>Carnethon</surname><given-names>M</given-names></name><name><surname>De Simone</surname><given-names>G</given-names></name><name><surname>Ferguson</surname><given-names>TB</given-names></name><name><surname>Flegal</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Heart disease and stroke statistics-2009 update: a report from the
American Heart Association statistics committee and stroke statistics
subcommittee</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>3</issue><fpage>e21</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">19075105</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Bhargava</surname><given-names>B</given-names></name><name><surname>Narang</surname><given-names>R</given-names></name><name><surname>Ray</surname><given-names>R</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Gulati</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>The ABCD Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial
a long-term follow-up study</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><issue>15</issue><fpage>1643</fpage><lpage>1644</lpage><pub-id pub-id-type="pmid">20378086</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer-Rasokat</surname><given-names>U</given-names></name><name><surname>Assmus</surname><given-names>B</given-names></name><name><surname>Seeger</surname><given-names>FH</given-names></name><name><surname>Honold</surname><given-names>J</given-names></name><name><surname>Leistner</surname><given-names>D</given-names></name><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>A pilot trial to assess potential effects of selective intracoronary
bone marrow-derived progenitor cell infusion in patients with nonischemic dilated
cardiomyopathy: final 1-year results of the transplantation of progenitor cells
and functional regeneration enhancement pilot trial in patients with nonischemic
dilated cardiomyopathy</article-title><source>Circ Heart Fail</source><year>2009</year><volume>2</volume><issue>5</issue><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">19808371</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vrtovec</surname><given-names>B</given-names></name><name><surname>Poglajen</surname><given-names>G</given-names></name><name><surname>Lezaic</surname><given-names>L</given-names></name><name><surname>Sever</surname><given-names>M</given-names></name><name><surname>Domanovic</surname><given-names>D</given-names></name><name><surname>Cernelc</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Effects of intracoronary CD34+ stem cell transplantation in
nonischemic dilated cardiomyopathy patients: 5-year follow-up</article-title><source>Circ Res</source><year>2013</year><volume>112</volume><issue>1</issue><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">23065358</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>M</given-names></name><name><surname>Tomita</surname><given-names>S</given-names></name><name><surname>Nakatani</surname><given-names>T</given-names></name><name><surname>Fukuhara</surname><given-names>S</given-names></name><name><surname>Hamamoto</surname><given-names>M</given-names></name><name><surname>Nagaya</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Bone marrow mononuclear cell transplantation had beneficial effects on
doxorubicin-induced cardiomyopathy</article-title><source>J Heart Lung Transplant</source><year>2004</year><volume>23</volume><issue>4</issue><fpage>436</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">15063403</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Iwase</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>S</given-names></name><name><surname>Miyahara</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Transplantation of mesenchymal stem cells improves cardiac function in
a rat model of dilated cardiomyopathy</article-title><source>Circulation</source><year>2005</year><volume>112</volume><issue>8</issue><fpage>1128</fpage><lpage>1135</lpage><pub-id pub-id-type="pmid">16103243</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>M</given-names></name><name><surname>Wollert</surname><given-names>KC</given-names></name><name><surname>Meyer</surname><given-names>GP</given-names></name><name><surname>Menke</surname><given-names>A</given-names></name><name><surname>Arseniev</surname><given-names>L</given-names></name><name><surname>Hertenstein</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Monitoring of bone marrow cell homing into the infarcted human
myocardium</article-title><source>Circulation</source><year>2005</year><volume>111</volume><issue>17</issue><fpage>2198</fpage><lpage>2202</lpage><pub-id pub-id-type="pmid">15851598</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sant'anna</surname><given-names>RT</given-names></name><name><surname>Kalil</surname><given-names>RA</given-names></name><name><surname>Pretto</surname><given-names>AS</given-names><suffix>Neto</suffix></name><name><surname>Pivatto</surname><given-names>F</given-names><suffix>J&#x000fa;nior</suffix></name><name><surname>Fracasso</surname><given-names>J</given-names></name><name><surname>Sant'anna</surname><given-names>JR</given-names></name><etal>et al</etal></person-group><article-title>Global contractility increment in nonischemic dilated cardiomyopathy
after free wall-only intramyocardial injection of autologous bone marrow
mononuclear cells: an insight over stem cells clinical mechanism of
action</article-title><source>Cell Transplant</source><year>2010</year><volume>19</volume><issue>8</issue><fpage>959</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">20546674</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>VO</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>GV</given-names></name><name><surname>Carrara</surname><given-names>D</given-names></name><name><surname>Bacal</surname><given-names>F</given-names></name><name><surname>Bocchi</surname><given-names>EA</given-names></name></person-group><article-title>Validation of the Portuguese version of the Minnesota Living with
Heart Failure Questionnaire</article-title><source>Arq Bras Cardiol</source><year>2009</year><volume>93</volume><issue>1</issue><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">19838469</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>WC</given-names></name><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Linker</surname><given-names>DT</given-names></name><name><surname>Sutradhar</surname><given-names>SC</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Cropp</surname><given-names>AB</given-names></name><etal>et al</etal></person-group><article-title>The Seattle Heart Failure Model: prediction of survival in heart
failure</article-title><source>Circulation</source><year>2006</year><volume>113</volume><issue>11</issue><fpage>1424</fpage><lpage>1433</lpage><pub-id pub-id-type="pmid">16534009</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><article-title>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL
Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF)</article-title><source>Lancet</source><year>1999</year><volume>353</volume><issue>9169</issue><fpage>2001</fpage><lpage>2007</lpage><pub-id pub-id-type="pmid">10376614</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ly</surname><given-names>HQ</given-names></name><name><surname>Nattel</surname><given-names>S</given-names></name></person-group><article-title>Stem cells are not proarrhythmic: letting the genie out of the
bottle</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>13</issue><fpage>1824</fpage><lpage>1831</lpage><pub-id pub-id-type="pmid">19349335</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macia</surname><given-names>E</given-names></name><name><surname>Boyden</surname><given-names>PA</given-names></name></person-group><article-title>Stem cell therapy is proarrhythmic</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>13</issue><fpage>1814</fpage><lpage>1823</lpage><pub-id pub-id-type="pmid">19349334</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Latif</surname><given-names>A</given-names></name><name><surname>Bolli</surname><given-names>R</given-names></name><name><surname>Tleyjeh</surname><given-names>IM</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name><name><surname>Perin</surname><given-names>EC</given-names></name><name><surname>Hornung</surname><given-names>CA</given-names></name><etal>et al</etal></person-group><article-title>Adult bone marrow-derived cells for cardiac repair: a systematic
review and meta-analysis</article-title><source>Arch Intern Med</source><year>2007</year><volume>167</volume><issue>10</issue><fpage>989</fpage><lpage>997</lpage><pub-id pub-id-type="pmid">17533201</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Ramshorst</surname><given-names>J</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Beeres</surname><given-names>SL</given-names></name><name><surname>Dibbets-Schneider</surname><given-names>P</given-names></name><name><surname>Roes</surname><given-names>SD</given-names></name><name><surname>Stokkel</surname><given-names>MP</given-names></name><etal>et al</etal></person-group><article-title>Intramyocardial bone marrow cell injection for chronic myocardial
ischemia: a randomized controlled trial</article-title><source>JAMA</source><year>2009</year><volume>301</volume><issue>19</issue><fpage>1997</fpage><lpage>2004</lpage><pub-id pub-id-type="pmid">19454638</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>Randomized study of mononuclear bone marrow cell transplantation in
patients with coronary surgery</article-title><source>Ann Thorac Surg</source><year>2008</year><volume>86</volume><issue>6</issue><fpage>1833</fpage><lpage>1840</lpage><pub-id pub-id-type="pmid">19021989</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MG</given-names></name><name><surname>Tung</surname><given-names>L</given-names></name><name><surname>Sekar</surname><given-names>RB</given-names></name><name><surname>Chang</surname><given-names>CY</given-names></name><name><surname>Cysyk</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Proarrhythmic potential of mesenchymal stem cell transplantation
revealed in an in vitro coculture model</article-title><source>Circulation</source><year>2006</year><volume>113</volume><issue>15</issue><fpage>1832</fpage><lpage>1841</lpage><pub-id pub-id-type="pmid">16606790</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeres</surname><given-names>SL</given-names></name><name><surname>Atsma</surname><given-names>DE</given-names></name><name><surname>van der Laarse</surname><given-names>A</given-names></name><name><surname>Pijnappels</surname><given-names>DA</given-names></name><name><surname>van Tuyn</surname><given-names>J</given-names></name><name><surname>Fibbe</surname><given-names>WE</given-names></name><etal>et al</etal></person-group><article-title>Human adult bone marrow mesenchymal stem cells repair experimental
conduction block in rat cardiomyocyte cultures</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>46</volume><issue>10</issue><fpage>1943</fpage><lpage>1952</lpage><pub-id pub-id-type="pmid">16286184</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pijnappels</surname><given-names>DA</given-names></name><name><surname>Schalij</surname><given-names>MJ</given-names></name><name><surname>van Tuyn</surname><given-names>J</given-names></name><name><surname>Ypey</surname><given-names>DL</given-names></name><name><surname>de Vries</surname><given-names>AA</given-names></name><name><surname>van der Wall</surname><given-names>EE</given-names></name><etal>et al</etal></person-group><article-title>Progressive increase in conduction velocity across human mesenchymal
stem cells is mediated by enhanced electrical coupling</article-title><source>Cardiovasc Res</source><year>2006</year><volume>72</volume><issue>2</issue><fpage>282</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">16956599</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukushima</surname><given-names>S</given-names></name><name><surname>Varela-Carver</surname><given-names>A</given-names></name><name><surname>Coppen</surname><given-names>SR</given-names></name><name><surname>Yamahara</surname><given-names>K</given-names></name><name><surname>Felkin</surname><given-names>LE</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Direct intramyocardial but not intracoronary injection of bone marrow
cells induces ventricular arrhythmias in a rat chronic ischemic heart failure
model</article-title><source>Circulation</source><year>2007</year><volume>115</volume><issue>17</issue><fpage>2254</fpage><lpage>2261</lpage><pub-id pub-id-type="pmid">17438152</pub-id></element-citation></ref></ref-list></back></article>